Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Forty Seven is a clinical-stage immuno-oncology company focused on developing nove...
Forty Seven is a clinical-stage immuno-oncology...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW) is a medical device company that is ...
Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW) i...
Silk Road Medical is a medical device company focused on reducing the risk of stro...
Silk Road Medical is a medical device company f...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Atreca is a biotechnology company developing novel therapeutics drawn from human i...
Atreca is a biotechnology company developing no...
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
Join the National Investor Network and get the latest information with your interests in mind.